Meeting On The Mesa: China Seen As Competitive Threat, Even In Cell And Gene Therapy
Investors at the Cell & Gene Meeting on the Mesa expressed concern, though it may be a while before China can become a serious competitor in cell and gene therapy versus “me-better” drugs.
Scrip - October 7, 2026

After Monotherapy Miss, Cerevance’s Solengepras Clears Phase III As Parkinson’s Add-On
Having failed a Phase II study for Parkinson’s monotherapy with its first-in-class GPR6 inhibitor, Cerevance will discuss the Phase III data showing benefit with solengepras as an adjunctive therapy with the US FDA.
Scrip - October 7, 2026

Top Tips For Spanish Biotechs Hoping To Make It Big
Spain has developed a reputation for excellent science and a top destination in Europe to conduct clinical trials. Now its budding biotechs are looking to make headway in choppy commercial waters as the sector continues to mature.
Scrip - October 7, 2026

Lycia Plans IPO To Fund Next-Generation Protein Degraders
The South San Francisco company is developing therapies that target extracellular proteins, and its lead candidate is a food allergy therapy.
Scrip - October 7, 2026

Vertex CDIO On Operating Model Shifts And The Case For ‘Unreasonable Goals’
Vertex Pharmaceuticals’ CDIO Agam Upadhyay outlines the firm’s three-pronged AI approach, the value realization framework keeping every deployment accountable and the CEO's seemingly impossible ask that led to striking AI win.
Scrip - October 7, 2026

BioBytes: AI-Related Deals In Q3 ‘26
AI biotech funding in Q3 showed that capital is spreading across drug discovery, clinical development and the infrastructure connecting AI to the lab.
Scrip - October 7, 2026

First Devices Selected For EU Joint Assessment Process That Has Faced Pharma Skepticism
Edwards and Highlife’s mitral valve replacement systems will receive health technology assessment (HTA) at an EU level via a process designed for high-risk devices that can address unmet needs.
Medtech Insight - October 8, 2026

Beauty Dealmaking Themes: Scale, Science and AI
From Sojourner's $279m merger of Lornamead and AMG Brands to Estée Lauder's AI-search partnership with Profound, recent deals show beauty companies pursuing growth through scale, science and technology.
HBW Insight - October 7, 2026

‘Nature’s Ozempic’ And Ashwagandha Top Trending Supplements List Across US, Europe In 2026
Ashwagandha tops consumer search interest across the US and five European markets, according to HBW Insight's Google Trends analysis of 50 supplements. Iron, sleep and CoQ10 complete the top four, while berberine ranks seventh, despite facing growing regulatory scrutiny in Europe.
HBW Insight - October 7, 2026

AESGP Switch Day: Self-Medication A ‘Strategic’ Priority For Europe, Commission Says
EU Health Commissioner Olivér Várhelyi told AESGP's first Switch Day that self-medication is "strategic" for Europe, as pharma reform bringing new shortage duties for OTC companies nears entry into force.
HBW Insight - October 7, 2026

CRN Back To Court Where It Started Challenging New York Age-Restricted Supplement Sales Law
Supreme Court denial of appeals to hear more than 700 cases during its current term includes rejection of CRN’s petition for a writ of certiorari in its complaint against New York restricting sales of weight loss and bodybuilding supplements to consumers 18 and older.
HBW Insight - October 7, 2026

Amazon, Walmart Warned About STI Treatment Claims For OTC Topicals, Including Homeopathics
Warnings mark a first for FDA about OTC topicals rendered unapproved due to labeling for STI treatment and latest action to remind consumer health products sector that since 2022 agency made homeopathics subject to same regulations as other types of drugs.
HBW Insight - October 7, 2026

Kamada Expands Biosimilar Portfolio With Stelara And Clexane Rival Launches In Israel
Kamada has launched ustekinumab and enoxaparin biosimilars in Israel, though its current $10m 2028 revenue target is significantly below the $40m peak it projected in 2022.
Generics Bulletin - October 8, 2026

Desai Takes Aim At Canadian Biosimilars With Launch Of Palindrome Pharma
Former Apotex chief executive Jeremy Desai is launching a new Canadian biosimilars company under the banner of Palindrome Pharma.
Generics Bulletin - October 8, 2026

Rare To Blockbuster: Expansion Strategies In Non-Oncology Precision Medicine
Setmelanotide grew from $3m to $195m in annual sales by stretching one mechanism across rare and acquired obesity, and a handful of non-oncology precision medicines in the pipeline are now attempting the same trick on far larger patient populations.
In Vivo - October 7, 2026

MIT’s Barzilay Wants AI To Predict Who Responds
Since her 2014 breast cancer diagnosis, MIT's Regina Barzilay has built artificial intelligence tools for screening and drug discovery. Now she is developing AI to predict which patients will respond to which treatments.
In Vivo - October 7, 2026